by Maria Zannes | Oct 10, 2023 | Press Releases
CEO Maria Zannes to hold one-on-one investor meetings and present a corporate update highlighting commercial strategy SAN ANTONIO, Texas (Oct. 10, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for...
by Maria Zannes | Sep 27, 2023 | Articles, News
Sept. 26, 2023 As published in 360Dx By Greg Cima NEW YORK – bioAffinity has its eyes on expanding sales of its sputum-based lung cancer test nationwide through its recent acquisition of the pathology laboratory that had licensed and developed that technology into a...
by Maria Zannes | Sep 19, 2023 | Press Releases
Transformative Strategic Transaction Supports Commercialization of CyPath® Lung Precision Pathology Founder Dr. Roby Joyce Joins bioAffinity’s Board of Directors Conference Call at 4:30 p.m. Eastern time Today SAN ANTONIO, Texas (Sept. 19, 2023) – bioAffinity...
by Maria Zannes | Sep 7, 2023 | Press Releases
SAN ANTONIO, Texas (Sept. 7, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer, today announced that Maria Zannes, President and CEO, will present a corporate...
by Maria Zannes | Aug 10, 2023 | Press Releases
SAN ANTONIO, Texas (Aug. 14, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three...
